how to calculate kla, mixing time for mammalian cell culture like cho cell line

The volumetric mass transfer coefficient (Kla) and mixing time are important parameters in the design and optimization of bioreactors for mammalian cell culture, such as CHO cell lines.

To calculate Kla, one common method is to use the dynamic gassing-out method. In this method, a known volume of gas is injected into the bioreactor, and the rate of oxygen consumption by the cells is measured over time. The Kla can then be calculated using the following equation:

Kla = (d(DO) / dt) / (C*(S-X))

Where d(DO)/dt is the rate of oxygen consumption, C is the oxygen solubility in the liquid, S is the oxygen saturation concentration, and X is the dissolved oxygen concentration in the liquid.

To calculate mixing time, one common method is to use the "tracer response method". In this method, a small amount of a non-toxic tracer, such as fluorescein, is added to the bioreactor. The mixing time can then be calculated as the time taken for the tracer to be homogeneously distributed throughout the bioreactor.

It's worth noting that these methods are widely used but are not the only way to calculate kla and mixing time. Other methods such as the "gas pulse" method or "respirometry" can also be used to calculate kla, while the "pulsed field gradient" method or "Particle Image Velocimetry" (PIV) can also be used to calculate mixing time. Also, many commercial software and systems available to measure kla and mixing time.

In any case, it is important to keep in mind that these parameters can be affected by various factors such as the bioreactor design, the cell density, the medium composition, and the agitation rate, so it is important to optimize the culture conditions and the bioreactor design to achieve the best performance.

Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more